负荷量他汀对急性冠脉综合征择期经皮冠脉介入治疗术后细胞凋亡及心肌损伤和临床事件的影响

被引:6
作者
朱记法 [1 ,2 ]
马虹 [1 ]
李怡 [1 ]
机构
[1] 中山大学第一附属医院心内科
[2] 郑州大学第一附属医院心内科
基金
广东省科技计划;
关键词
经皮冠脉介入治疗; 细胞凋亡; 阿托伐他汀;
D O I
暂无
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)];
学科分类号
1002 ; 100201 ;
摘要
【目的】探讨急性冠脉综合征患者择期经皮冠脉介入术前给予负荷量阿托伐他汀对细胞凋亡、心肌损伤及术后主要不良心血管事件的影响。【方法】入选2008年11月至2009年7月在我院行择期冠脉介入术的急性冠脉综合征连续病例85例,随机分为试验组和对照组,分别为42例和43例。试验组在阿托伐他汀20 mg/d基础上,术前8 h再给予负荷量阿托伐他汀80 mg,对照组仅给予阿托伐他汀20 mg/d。分别在术前,术后6 h及术后24 h检测凋亡因子Fas,术前及术后24 h检测心肌损伤标记物肌钙蛋白T(cTnT),并随访术后3个月内的主要不良心血管事件。【结果】试验组Fas水平在PCI术前,术后6 h及24 h依次降低,但差异无统计学意义。在对照组,术后24 hFas水平较术后6 h有升高趋势(P=0.056)。试验组与对照组间比较,两组术前与术后6 h细胞凋亡因子Fas水平差异无统计学意义;术后24 h试验组细胞凋亡因子Fas水平较对照组明显降低,两组比较差异有统计学意义。试验组心肌损伤标记物cTnT在PCI术后24 h较术前降低,差异有统计学意义。对照组术后24 h较术前升高,但差异无统计学意义。试验组与对照组间比较,试验组cTnT在术后24 h明显低于对照组。随访3个月,试验组有6例患者发生主要不良心血管事件,对照组有14例患者发生不良心血管事件,差异有统计学意义。【结论】本研究初步表明,急性冠脉综合征患者择期PCI术后细胞凋亡因子Fas水平有增高趋势,术前8 h给予负荷量阿托伐他汀能够降低术后细胞凋亡因子Fas水平,并能减轻心肌损伤,减少术后3个月内的主要不良心血管事件。
引用
收藏
页码:67 / 70+80 +80
页数:5
相关论文
共 7 条
[1]   强化阿托伐他汀对冠状动脉介入治疗的心肌保护作用 [J].
张瑞生 ;
季福绥 ;
何青 ;
孙福成 ;
许锋 .
中国心血管杂志, 2008, (03) :191-194
[2]   C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes [J].
Jin Yang ;
Junhong Wang ;
Shushu Zhu ;
Xiangjian Chen ;
Hengfang Wu ;
Di Yang ;
Jinan Zhang .
Molecular and Cellular Biochemistry, 2008, 310 :215-226
[3]  
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention[J] . Giuseppe Patti,Vincenzo Pasceri,Giuseppe Colonna,Marco Miglionico,Dionigi Fischetti,Gennaro Sardella,Antonio Montinaro,Germano Di Sciascio.Journal of the American College of Cardiology . 2007 (12)
[4]  
Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention[J] . Giuseppe Patti,Massimo Chello,Vincenzo Pasceri,Diego Colonna,Annunziata Nusca,Marco Miglionico,Andrea D’Ambrosio,Elvio Covino,Germano Di Sciascio.Journal of the American College of Cardiology . 2006 (8)
[5]  
Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study[J] . Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio.Circulation . 2004 (6)
[6]  
ANTI‐APOPTOTIC EFFECT OF ATORVASTATIN, A 3‐HYDROXY‐3‐METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR, ON CARDIAC MYOCYTES THROUGH PROTEIN KINASE C ACTIVATION[J] . KoichiTanaka,MasaakiHonda,ToshikazuTakabatake.Clinical and Experimental Pharmacology and Physiology . 2004 (5‐6)
[7]  
Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model[J] . Merce Roque,Carlos Cordon-Cardo,Valentin Fuster,Ernane D. Reis,Marija Drobnjak,Juan J. Badimon.Atherosclerosis . 2000 (2)